-
公开(公告)号：US20180265851A1
公开(公告)日：2018-09-20
申请号：US15763677
申请日：2016-09-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Chetana RAO-NAIK , Ganapathy N. SARMA , Akbar NAYEEM
CPC classification number: C12N9/1044 , A61K47/68 , A61K47/6803 , A61K47/6849 , C12P21/00 , C12Y203/02013
Abstract: Transglutaminase variants capable of conjugating an antibody that is not conjugated by wild-type transglutaminase from Streptomyces mobaraensis.
-
公开(公告)号：US20220153856A1
公开(公告)日：2022-05-19
申请号：US17588518
申请日：2022-01-31
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K47/68 , A61K39/395 , C07K16/46 , A61P37/00
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20240124597A1
公开(公告)日：2024-04-18
申请号：US18453691
申请日：2023-08-22
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K45/06 , A61K47/6803
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
Patent Agency Ranking
公开(公告)号：US20210054090A1
公开(公告)日：2021-02-25
申请号：US17080626
申请日：2020-10-26
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K47/68 , A61K39/395 , A61K45/06
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20240239909A1
公开(公告)日：2024-07-18
申请号：US18441998
申请日：2024-02-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K39/395 , A61K47/68 , A61P37/00 , C07K16/46 , C12N15/63 , A61K39/00 , A61K45/06 , C07K14/705
CPC classification number: C07K16/2878 , A61K39/3955 , A61K47/68 , A61K47/6849 , A61P37/00 , C07K16/468 , C12N15/63 , A61K2039/505 , A61K45/06 , A61K47/6803 , C07K14/70578 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/71 , C07K2317/76 , C07K2317/92
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20220169742A1
公开(公告)日：2022-06-02
申请号：US17670223
申请日：2022-02-11
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, Jr. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K47/68 , A61K39/395 , C07K16/46 , A61P37/00
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20220144962A1
公开(公告)日：2022-05-12
申请号：US17579468
申请日：2022-01-19
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K47/68 , A61K39/395 , C07K16/46 , A61P37/00
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
公开(公告)号：US20200157233A1
公开(公告)日：2020-05-21
申请号：US16686596
申请日：2019-11-18
Applicant: Bristol-Myers Squibb Company
Inventor： Aaron YAMNIUK , Mary STRUTHERS , Stanley R. KRYSTEK, JR. , Akbar NAYEEM , Ginger RAKESTRAW
IPC: C07K16/28 , A61K47/68 , A61K39/395 , A61K45/06
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.016 seconds)
